1107 |
Fear Not! |
Paul S. Teirstein |
May. 03. 10 |
1106 |
Insights from EVEREST II: Clinical Utility of Transcatheter Edge-to-Edge Mitral Valve Repair |
William A. Gray |
May. 03. 10 |
1105 |
New TAVI Devices: More of the Same or Meaningful Differences? |
Eberhard Grube |
May. 03. 10 |
1104 |
Status Update and Clinical Impact of Transcatheter Aortic Valve Implantation (TAVI) |
Martin Bert Leon |
May. 03. 10 |
1103 |
Does PROSPECT Support the Use of Invasive Imaging to Diagnose and Treat Vulnerable Plaque with DES? |
Gregg W. Stone |
May. 03. 10 |
1102 |
My Crystal Ball - New Drug Delivery Platforms and Bioabsorbable Stents will Dominate in the Next 5-10 Years! |
Martin Bert Leon |
May. 03. 10 |
1101 |
The Role of New Anti-platelet Agents: Will Prasugrel and Ticagrelor Change the DES Landscape? |
Roxana Mehran |
May. 03. 10 |
1100 |
Dual-Antiplatelet Therapy Dilemmas - Drug Dosing and Duration, Rebound, and Platelet Monitoring |
Donald E. Cutlip |
May. 03. 10 |
1099 |
Addressing the Lingering Concerns of Late DES Safety and Efficacy? |
Ajay J. Kirtane |
May. 03. 10 |
1098 |
Introducing EXCEL: The \"Definitive\" Unprotected Left Main Randomized Trial! |
Gregg W. Stone |
May. 03. 10 |